Ligand Pharmaceuticals
LGND
212 hedge funds and large institutions have $2.09B invested in Ligand Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 71 increasing their positions, 77 reducing their positions, and 34 closing their positions.
151% more call options, than puts
Call options by funds: $33.4M | Put options by funds: $13.3M
2.88% more ownership
Funds ownership: 92.86% → 95.74% (+2.9%)
8% less repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 77
7% less funds holding
Funds holding: 227 → 212 (-15)
11% less capital invested
Capital invested by funds: $2.35B → $2.09B (-$261M)
44% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 34
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$30.8M |
| 2 |
Janus Henderson Group
London,
|
+$24.9M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$14.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$10.2M |
| 5 |
SDJVC
St. Denis J. Villere & Co
New Orleans,
Louisiana
|
+$7.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$11.7M |
| 2 |
BlackRock
New York
|
-$10.9M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$9.14M |
| 4 |
Norges Bank
Oslo,
Norway
|
-$8.08M |
| 5 |
CCA
Conestoga Capital Advisors
Wayne,
Pennsylvania
|
-$7.34M |
LGND Hedge Fund Activity: Q2 2021 in Review
212 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2021, worth a combined $2.09B — down 11% from $2.35B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of LGND and 19 opened new positions — a net loss of 15 holders — while 77 trimmed existing stakes and 71 added.
The largest buyer was Aberdeen Group, adding an estimated $30.8M. The largest seller was Granahan Investment Management, cutting an estimated $11.7M.
- 212 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2021, down from 227 in Q1 2021.
- Funds reported $2.09B of Ligand Pharmaceuticals stock for Q2 2021, down 11% quarter-over-quarter.
- 19 funds opened new Ligand Pharmaceuticals positions in Q2 2021 and 34 closed out, a net change of -15 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2021 was Aberdeen Group, an estimated $30.8M added.
- The largest Ligand Pharmaceuticals seller in Q2 2021 was Granahan Investment Management, an estimated $11.7M sold.
Based on aggregated 13F filings for Q2 2021.